REOLYSIN® + Carboplatin + Paclitaxel
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Non-small Cell Lung
Conditions
Carcinoma, Non-small Cell Lung
Trial Timeline
Mar 1, 2009 → Nov 1, 2015
NCT ID
NCT00861627About REOLYSIN® + Carboplatin + Paclitaxel
REOLYSIN® + Carboplatin + Paclitaxel is a phase 2 stage product being developed by Oncolytics Biotech for Carcinoma, Non-small Cell Lung. The current trial status is completed. This product is registered under clinical trial identifier NCT00861627. Target conditions include Carcinoma, Non-small Cell Lung.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma, Non-small Cell Lung were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00861627 | Phase 2 | Completed |
| NCT00753038 | Phase 2 | Completed |
Competing Products
20 competing products in Carcinoma, Non-small Cell Lung